Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02633943 · ClinicalTrials.gov registry record

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

A clinical trial of Transfusion-dependent Beta-Thalassemia, sponsored by Genetix Biotherapeutics.

Active
Registry status
66
Enrollment target
15
Study locations

NCT02633943 is a study of Transfusion-dependent Beta-Thalassemia that is active but no longer recruiting, run by Genetix Biotherapeutics. The registered enrollment target is 66 participants, below the 91-participant average among 3 other Transfusion-dependent Beta-Thalassemia trials with a reported enrollment target (27% lower). The trial reports 15 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02633943, a study of Transfusion-dependent Beta-Thalassemia, is active but no longer recruiting, sponsored by Genetix Biotherapeutics.

ACTIVE NOT RECRUITING
Registry status
66 participants
Enrollment target
15
Study locations

Study Summary

This is a multi-center, long-term safety and efficacy follow-up study for subjects with transfusion-dependent β-thalassemia (TDT) who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored parent clinical studies. After completing the parent clinical studies (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.

Conditions Studied

Transfusion-dependent Beta-Thalassemia

Interventions

  • OTHER Safety and efficacy assessments

Study Locations (15)

Other

  • - Sydney
  • - Marseille
  • - Paris
  • - Hanover
  • - Heidelberg
  • - Thessaloniki
  • - Rome
  • - Bangkok
  • - London

California

  • - Oakland

Illinois

  • - Chicago

Maryland

  • - Bethesda

New York

  • - New York

Pennsylvania

  • - Philadelphia

South Carolina

  • - Charleston

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2014-01
Est. Completion 2035-11

Sponsor

Genetix Biotherapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02633943

The ClinicalTrials.gov registry entry for NCT02633943 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 3 other Transfusion-dependent Beta-Thalassemia trials with a reported enrollment target (27% lower). The listed sponsor is Genetix Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Transfusion-dependent Beta-Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which Safety and efficacy assessments is the first listed.

NCT02633943 reports 15 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT02633943 about?

NCT02633943 is a clinical study titled "Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy". This is a multi-center, long-term safety and efficacy follow-up study for subjects with transfusion-dependent β-thalassemia (TDT) who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored parent clinical studies. After completing the parent clinical studies (approximatel...

What is the current status of trial NCT02633943?

This trial is currently active not recruiting. The enrollment target is 66 participants. The study started on 2014-01. Estimated completion is 2035-11.

What conditions does trial NCT02633943 study?

This clinical trial studies the following conditions: Transfusion-dependent Beta-Thalassemia.

What interventions are being tested in trial NCT02633943?

The interventions under investigation include: Safety and efficacy assessments (OTHER).

Who is sponsoring clinical trial NCT02633943?

This trial is sponsored by Genetix Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02633943 being conducted?

This trial has 15 study locations across California, Illinois, Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Transfusion-dependent Beta-Thalassemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Transfusion-dependent Beta-Thalassemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.